Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$160 Mln
Revenue (TTM)
$10 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.1
Industry P/E
--
EV/EBITDA
-8.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.1
Face value
--
Shares outstanding
228,356,000
CFO
$-289.89 Mln
EBITDA
$-518.35 Mln
Net Profit
$-234.71 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lineage Cell Therapeutics (LCTX)
| 61.0 | 83.8 | 55.5 | -14.6 | -16.7 | -4.2 | -14.8 |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Lineage Cell Therapeutics (LCTX)
| -53.6 | -6.8 | -52.2 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lineage Cell Therapeutics (LCTX)
|
0.8 | 160.0 | 9.6 | -16.2 | -155.0 | -22.8 | -- | 2.1 |
| 51.0 | 8,079.8 | 1,208.8 | 131.7 | 13.4 | 6.3 | 62.1 | 3.9 | |
| 128.1 | 8,274.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 151.6 | 7,421.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 54.0 | 10,499.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.3 | |
| 41.6 | 11,298.3 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19.1 | 5.5 | |
| 302.7 | 8,688.9 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.4 | 14.6 | |
| 26.6 | 10,732.1 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.1 | |
| 125.2 | 12,288.6 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.4 | 4.9 | |
| 284.4 | 12,470.6 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 12.9 | 2.2 |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment... epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. Address: 2173 Salk Avenue, Carlsbad, CA, United States, 92008 Read more
CEO, President & Director
Mr. Brian M. Culley M.A., M.B.A.
CEO, President & Director
Mr. Brian M. Culley M.A., M.B.A.
Headquarters
Carlsbad, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lineage Cell Therapeutics Inc (LCTX) stood at $ 125 Mln as on 31-Mar-25
The share price of Lineage Cell Therapeutics Inc (LCTX) is $0.81 (NYSE) as of 13-Jun-2025 13:42 EDT. Lineage Cell Therapeutics Inc (LCTX) has given a return of -16.71% in the last 3 years.
Lineage Cell Therapeutics Inc (LCTX) has a market capitalisation of $ 160 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Lineage Cell Therapeutics Inc (LCTX) is 2.08 times as on 12-Jun-2025, a 22% discount to its peers’ median range of 2.65 times.
Since, TTM earnings of Lineage Cell Therapeutics Inc (LCTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lineage Cell Therapeutics Inc (LCTX) and enter the required number of quantities and click on buy to purchase the shares of Lineage Cell Therapeutics Inc (LCTX).
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. Address: 2173 Salk Avenue, Carlsbad, CA, United States, 92008
The CEO & director of Mr. Brian M. Culley M.A., M.B.A.. is Lineage Cell Therapeutics Inc (LCTX), and CFO & Sr. VP is Mr. Brian M. Culley M.A., M.B.A..
There is no promoter pledging in Lineage Cell Therapeutics Inc (LCTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Lineage Cell Therapeutics Inc. (LCTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-22.81
|
|
Operating margin(%)
|
-155.04
|
|
Net Margin(%)
|
-169.57
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Lineage Cell Therapeutics Inc (LCTX) was $0 Mln.
$0.11
(
